• Perimeter Medical Imaging AI published its MD&A for the three months ended March 31, 2026.
• FDA pre-market approval for Claire OCT, positioned for planned U.S. commercial launch for intraoperative breast cancer margin assessment.
• Revenue USD 384,604; net loss USD 2.98 million; cash USD 421,496 at quarter-end, citing need for additional financing.
• Entered Intermountain Health deployment agreement for S-Series OCT at LDS Hospital, American Fork Hospital.
• Closed financing rounds: CEO and SC Master Holdings debentures targeting about CAD 5.5 million; Life Offering raised CAD 7.52 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perimeter Medical Imaging AI Inc. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.